Berberine

The reviewed pilot reports HbA1c changes with berberine and metformin. Its small sample and treatment-failure exclusions do not establish equivalence.

A change in a laboratory marker, a test score and everyday function are different outcomes. A statistically detectable result does not by itself tell us whether someone would notice a worthwhile difference.

Check the measured endpoint, comparison and study population. The full profile preserves effect estimates and the source's clinical-significance assessment, including when that assessment is not supplied.

The claim to test: A within-group glucose change establishes general healthy-aging benefit.

What the reviewed records say:

The gap: Gastrointestinal adverse events were common across berberine arms. Other trials, including adenoma prevention, still need full-text review; long-term safety is unresolved.

Durability, effects in other populations and healthy-lifespan outcomes need their own evidence.

Independent replication, meaningful human outcomes, longer follow-up and better safety reporting would make these results easier to interpret.

Gastrointestinal adverse events were common across berberine arms. Other trials, including adenoma prevention, still need full-text review; long-term safety is unresolved.